Adeno-Associated Virus– tag –
-
Fujifilm Diosynth Commits $2 Billion to North Carolina Gene Therapy Facility Amid Supply Chain Shifts; India Emerges as Key CDMO Hub
BioSpace Global Overview Fujifilm Diosynth is investing approximately $2 billion in a new gene therapy manufacturing facility in North Carolina, strategically positioning against global supply chain shifts. Catalent, under Novo Holdings,... -
Forge Biologics Advances AAV Manufacturing with Optimized FUEL Platform and Announces Strategic Expansion into Asia-Pacific Gene Therapy Market
Forge Biologics USA Overview Forge Biologics has announced advancements in its FUEL platform for adeno-associated virus (AAV) manufacturing. This optimization aims to enhance vector yield and consistency during process scale-up through r... -
eBioHippo Publishes Beginner’s Guide to AAV Gene Delivery: Detailing HEK293T and Baculovirus Expression Systems, Discussing Challenges
eBioHippo USA Overview eBioHippo has released a comprehensive beginner's guide to AAV gene delivery, covering key production methods like HEK293T cell triple transfection and baculovirus/Sf9 insect cell systems for scalable manufacturing... -
Drug Discovery News Analyzes Viral Vector Manufacturing Scale-Up Challenges for Gene Therapies, Highlighting AAV Production Bottlenecks
Drug Discovery News USA Overview Drug Discovery News focuses on the significant scale-up challenges in viral vector manufacturing for gene therapies, particularly emphasizing bottlenecks in adeno-associated virus (AAV) production. The ar... -
Drug Discovery News Identifies Critical Bottlenecks in Cell & Gene Therapy Manufacturing: Low Viral Vector Purification Yields and Plasmid DNA Supply Shortages
Drug Discovery News USA Overview Drug Discovery News highlights severe bottlenecks in cell and gene therapy (CGT) manufacturing, specifically in viral vector production. Low downstream purification yields for adeno-associated virus (AAV)... -
SNS Insider Analysis: Viral Vector Manufacturing Market Surges as Leading CDMOs Expand Capacity with Advanced AAV and Lentiviral Technologies
SNS Insider India Overview SNS Insider's market overview highlights that the increasing number of gene therapy clinical trials and the reliance on CDMOs are driving growth in the viral vector manufacturing market. Key CDMOs like Fujifilm... -
ProBio’s AAV Manufacturing Excellence Accelerates UC Irvine and GlyTR Therapeutics’ Pan-Cancer CAR-T Program, Achieving 80% CAR Gene Insertion Efficiency
University of California, Irvine USA Overview ProBio's advanced AAV manufacturing technology is critically powering pre-IND research for the first-in-class pan-cancer CAR-T program developed by UC Irvine and GlyTR Therapeutics. ProBio's ... -
CDMO Strategies Advance Next-Gen Biopharma: Automated Closed Systems Tackle Manufacturing Shortages
World Pharma Today Global Overview Contract Development and Manufacturing Organizations (CDMO) strategies are evolving towards end-to-end service models to support the surge in next-generation biopharmaceuticals, especially cell and gene... -
SK pharmteco Unveils SKyvec™ Viral Vector Platform, Boosting AAV Productivity by 5-6 Fold for Gene Therapy Development
Contract Pharma Global Overview SK pharmteco has launched its innovative 'SKyvec™ Viral Vector Platform,' designed to accelerate gene therapy development. This platform supports adeno-associated virus (AAV), lentivirus, and adenovirus ve... -
Cell Therapy Startups Like Orca Bio and Allogene Lead Cancer & Autoimmune Disease Treatment with Off-the-Shelf Platforms
New Market Pitch USA Overview Cell therapy startups such as Orca Bio and Allogene, utilizing off-the-shelf platforms, are spearheading advancements in allogeneic and iPSC-derived therapies for cancer and autoimmune diseases. Key differen...
